Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 12, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details changes in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan"):
- June 2, 2006: Holdings increased from 17,377,725 to 17,452,889 ADRs at an average price of $55.98.
- June 8, 2006: Holdings decreased from 17,452,889 to 17,444,240 ADRs at an average price of $55.99.
These movements were driven by fund activity within the Plan, a discretionary fund for current and former employees.
Management Commentary and Risks
The filing notes that two directors, Dr. J P Garnier and Dr. M Slaoui, are potentially interested in the shares held in the fund in the same capacity as other employees. The notification was made in accordance with Disclosure Rule 3.1.4R(1)(b). No specific risks, contingencies, or unusual items regarding the company's operations were disclosed in this text.
Investor Verification Points
- Verify the total aggregate holdings of the GlaxoSmithKline US Retirement Savings Plan to assess the scale of employee ownership.
- Confirm the specific beneficial ownership interests of Directors Dr. J P Garnier and Dr. M Slaoui relative to the Plan's holdings.
- Review the Plan's investment strategy to understand the frequency and drivers of these ADR movements.